Corporate Presentation

Spring 2020

NASDAQ: BSGM
Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig’s products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig’s control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig’s products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig’s ability to effectively react to other risks and uncertainties described from time to time in BioSig’s SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
BioSig Technologies Positioned for Success

- **Multi-billion dollar** electrophysiology (EP) market
  - Demand driven by high prevalence of arrhythmia
  - Procedures more efficacious than drugs, predicated on ability to analyze clean cardiac signals

- **Differentiated value proposition and impact to the patient**
  - Current standard of care negatively affected by signal “noise” and artifacts
  - PURE EP™ System offers a cleaner signal and potentially superior patient outcomes

- **Dynamic management team with significant commercial experience**
  - Recent investments in team positions the company for successful commercialization

- **Robust commercialization strategy – FDA approved product**
  - Supported by world-renowned key opinion leaders
  - Key relationships among clinicians at leading, high-volume centers

- **Positive clinical data**
  - Recognized by leaders in the field
  - Represents a seal of approval and speaks to the potential efficacy of the product

- **Strong intellectual property portfolio**
  - 26 allowed/issued worldwide design and utility patents

- **ViralClear subsidiary testing COVID-19 therapy**
Seasoned Management Team, Possessing the Necessary Skillset and Knowledge to Drive Commercialization

Kenneth L. Londoner, MBA
Founder, Chairman, CEO, Director
Endicott Management Partners, LLC
J & W Seligman & Co.

Steve Chaussy, CPA
CFO
Liberski Inc; Anna & Co; Penske Automotive; Ford Hogg and Cobbe

Andy Ballou
Vice President, Investor Relations
Janney Montgomery Scott; RBC Capital Markets

John Kowalski
Vice President, Sales
Biosense Webster (Johnson & Johnson)

Manasi Patwardhan
Director of Strategic Planning
Verily Life Sciences, Boston Scientific - Neuromodulation; Medtronic

Natasha Drapeau
Executive Vice President
Institute of Directors, UK; Augeous Consulting, Switzerland; IG Group Plc, UK

Barry Keenan, Ph.D, MBA, PMP
Vice President, Engineering
Medtronic; Nexeon MedSystems; Alfred Mann Institute for Biomedical Engineering; Alfred Mann Foundation for Scientific Research

Julie Stephenson, BSN, MBA
Vice President, Clinical Affairs
Medtronic; Boston Scientific; Guidant Corporation

Olivier Chaudoir
Senior Director, Marketing
Biosense Webster; DePuy Synthes
Defining the Market Opportunity

Global Growth in EP Devices:
$4.5B in 2017, projected to reach $7.4B in 2022
10.4% growth rate

Global Growth in Complex Cardiac Ablation Procedures:
440,629 in 2017 to 830,390 in 2022
13.5% growth rate

U.S.:
1,631 hospitals averaging 2.1 rooms per lab
3,425 EP rooms

OUS:
3,729 hospitals averaging 1.05 rooms per lab
3,915 EP rooms

Data source: 2018 MD&D report
Electrophysiology Market Overview

Consistent, long-term growth is driven by demographic trends and clinical evidence (ablation vs. drug therapy)

Key Market Players

- Abbott: 32%
- BioSense Webster: 42%
- Medtronic: 11%
- Boston Scientific: 8%
- Others: 7%

Global Market Share for Catheter Ablation Devices

- EP Ablation Catheters: 43%
- Access Devices: 12%
- 3D Mapping, Recording, Etc: 13%
- EP Diagnostic Catheters: 32%

PURE EP™ Developed Through Collaboration with Leading Centers

Relationships at leading, high-volume centers create traction for PURE EP™ in the market

2011
Concept developed with Texas Cardiac Arrhythmia Institute

2013
Proof of concept test completed at UCLA

2014
Prototype test with UCLA

2014
Initial pre-clinical planning at Mayo Clinic

2015
First pre-clinical trials at Mayo Clinic

2016
Advanced research at Mayo Clinic, trials at Mount Sinai

2016
Technology development partnership with Minnetronix

2017
Strategic collaboration with Mayo Clinic, first beta units, pre-FDA testing

2018
FDA 510(k) clearance

2019
First patient cases and first clinical trial

2020
Targeted commercial release of PURE EP™ System
Unique Collaboration with Mayo Clinic

• 10-year strategic agreement
  - Defines collaborative work plan
  - Spells out IP protection for both parties
  - Mayo Clinic has invested capital in the development of the PURE EP™ System

• Develop advanced clinical features and applications
  - PURE EP™ System versions 2.0 & 3.0

• Explore new disease areas and applications, leading to:
  - Joint IP filings
  - Licensing opportunities

• In January 2020, we announced the installation of PURE EP™ System at Mayo Clinic in Florida
Our First FDA-Cleared Product - PURE EP™ System: Addressing Unmet Clinical Need of More Reliable ECG Signals

PURE EP™ System provides innovative technology that fulfils unmet clinical needs while benefitting patients, physicians, and payors

- Signal processing platform designed to reveal the full range of cardiac signals and to provide electrophysiologists with signal clarity during catheter ablation procedures and related studies
- Refines signal clarity by reducing signal “noise” to allow clinicians to deliver therapy during the procedures with higher precision
- Allows surgeons to potentially work more accurately, decreasing the probability of a repeat procedure, and thus increasing the procedure’s safety and efficacy profile
- Reduced procedure time creates an economic incentive for hospitals and allows physicians to see more patients over a given time period
- Improved safety profile potentially creates a more favorable payor environment for reimbursement

PURE EP™ System provides innovative technology that fulfils unmet clinical needs while benefitting patients, physicians, and payors.
"With the use of the PURE EP™ System I was able to identify cardiac signals which were previously undetectable to me. I believe that the PURE EP™ System could change diagnostic and treatment strategies of arrhythmias, leading to more successful outcomes."

Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX. February 20, 2019

“We found that the clarity of the signals made a great difference in the confidence with which we could continue applying ablation energy to an abnormal pathway that was in the region of the normal conduction system; BioSig’s technology allowed us to see a clear signal from the normal conduction pathway during ablation that was obscured by noise on our standard recordings.”

Prof. John M. Miller, M.D., Indiana University School of Medicine. May 06, 2019
Our Clinical Path

PRE-CLINICAL STUDIES
• 23 studies
• Mayo Clinic, Mount Sinai, University of Pennsylvania
• Published peer reviews in leading journals

FIRST-IN-HUMAN CASES
• 21 patients
• TCAI, Greenville Memorial Hospital, University of Indiana
• Results shown improved signal fidelity

CLINICAL TRIAL
• >50 patients enrolled
• TCAI and Mayo Clinic FL
• Independent signal review is randomized and blinded
• Data to be presented in leading peer-reviewed publications
Business Model

**PURE EP™**
- Foundation of the business model starts with the PURE EP™ System
- Revenue from buying, leasing, and renting the product

**Service Agreements**
- Additional revenue from training, installation, and software upgrades

**Modules**
- Offers software solutions for clinically validated applications

**Data Sets**
- High-value annotated data for further applications
Presenting PURE EP™ at Leading Conferences in Order to Boost Awareness and Physician Support

AFIB SYMPOSIUM 2020
JAN 23-25
PLACE: Washington, DC

Spotlight Session: Innovation in EP
Dr. Andrea Natale

Booth: Technology Demonstration

Presentation: (i) Clinical and Economic Evidence Generation
(ii) Technical Data Collection and Abstracts

EP LIVE 2020
SEPT 2020
PLACE: Austin, TX
St David’s Medical Center

Formally Invited
Live Cases
New Approaches and Technologies in EP

VT Symposium
OCT 9-10
PLACE: New York City

Customer Engagement
Technology Demonstration focused on VT optimization

Technology Video
• THE CHALLENGE TODAY
• OUR SOLUTION
Key Milestones

**2020**
- ✔ Targeted commercial release of PURE EP™ System
- ✔ Publish first trial results and initiate new studies
- ✔ Present PURE EP™ at four large industry events
- ✔ Develop new product pipeline to complement PURE EP™
- ✔ File further IP

**2021**
- ✔ Accelerate commercialization in U.S.
- ✔ File further IP, advance R&D in bioelectronic medicine
- ✔ Clinical data publication and new evidence-based trials
- ✔ Gain European regulatory approval
Strong IP Strategy, Supported by Experts

26 allowed/issued worldwide design and utility patents, which cover various features of the PURE EP™ System’s display screens and graphical user interface for enhanced visualization of biomedical signals.

- Differentiated combination of hardware and software is supported by strong IP and serves as the main competitive advantage over competing systems.
- Sherpa Technology Group and Sterne Kessler Goldstein & Fox are effectively developing patent and IP strategy.
- Conducted a thorough Landscape Review to understand ability to successfully file patents.
- BioSig is an exclusive licensee of Mayo Clinic to several patents and applications covering software features of PURE EP™ and additional complementary technologies.
- All patents and applications are assigned or exclusively licensed to the company.
Subsidiary, ViralClear Pharmaceuticals, Develops an Anti-Viral to Treat COVID-19

- **Merimepodib**, lead compound, one of the most advanced products in development for COVID-19
  - Broad-spectrum, orally administered anti-viral
  - Ready to commence Phase II clinical testing at Mayo Clinic in May 2020
  - Studies to include in-hospital combination therapy with remdesivir and outpatient monotherapy trial
  - Extensive development work completed to shorten time to market
  - **Mayo Clinic** to be Principal Investigator, championed by Dr. Andrew Badley, head of the immunology lab at Mayo and Chairman of the COVID-19 Task Force
  - Subsidiary raised $10.8 million in May 2020

- **Exceptionally strong, expert management team**
  - Dr. Jerome B. Zeldis, former Chief Medical Officer of Celgene – Executive Chair
  - Nick Spring, former Head of Global Live Viral Vaccines franchise at Merck - CEO
  - Steve King, extensive small molecule outsourcing drug development expertise from development through to commercial launch - COO

- **Strong scientific rationale and data support treatment for COVID-19**
  - Immune modulation, tested at Galveston National Laboratory at UTMB
  - In-vitro studies shown 98% reduction in viral load
  - Strong synergy with remdesivir (Gilead Lifesciences), which is approved for emergency use in U.S.
  - First in-vitro data published in online peer-reviewed journal
  - Preliminary studies show that resistance is unlikely to develop

- **Clean safety profile**
  - Over 300 patients treated with no serious adverse events
  - Anticipated length of treatment is 14 days or less
  - Completed seven Phase I and five Phase II trials in other indications
## EP Sector M&A Activity

<table>
<thead>
<tr>
<th>Company</th>
<th>Formed</th>
<th>Proof of Concept</th>
<th>Prototype</th>
<th>Clinical Data</th>
<th>CE Mark</th>
<th>FDA</th>
<th>Sales</th>
<th>Acquirer/Investor</th>
<th>Valuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>BioSig Technologies</td>
<td>2009</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td>$291.6 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PHILIPS</td>
<td>May 19, 2020</td>
</tr>
<tr>
<td>EPD Solutions</td>
<td>2014</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td>PHILIPS</td>
<td>$563 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medtronic</td>
<td>June 2018</td>
</tr>
<tr>
<td>HeartWare</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td>Medtronic</td>
<td>$1.1 Billion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AURIS Surgical Robotics</td>
<td>June 2016</td>
</tr>
<tr>
<td>Hansen Medical</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td>Medtronic</td>
<td>$80 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Surgical Robotics</td>
<td>April 2016</td>
</tr>
<tr>
<td>nContact</td>
<td>2005</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td>Atthure</td>
<td>$149 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medtronic</td>
<td>Oct 2015</td>
</tr>
<tr>
<td>Cardioline</td>
<td>2006</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td>Medtronic</td>
<td>$272 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Surgical Robotics</td>
<td>June 2015</td>
</tr>
<tr>
<td>Topera Medical</td>
<td>2010</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td>Abbott</td>
<td>$350 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medical Equipment</td>
<td>Dec 2014</td>
</tr>
<tr>
<td>Endosense SA</td>
<td>2003</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td>St Jude Medical</td>
<td>$331 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Surgical Instruments</td>
<td>Aug 2013</td>
</tr>
<tr>
<td>Bard EP</td>
<td>Division of CR Bard</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td>Boston Scientific</td>
<td>$275 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medical Equipment</td>
<td>Nov 2013</td>
</tr>
<tr>
<td>Rhythmia Medical</td>
<td>2004</td>
<td>●</td>
<td>●</td>
<td></td>
<td>●</td>
<td>●</td>
<td></td>
<td>Boston Scientific</td>
<td>$410 million</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medical Equipment</td>
<td>Oct 2012</td>
</tr>
</tbody>
</table>
Business Model Summary

Highlights:

• PURE EP™ System expected to generate revenue beginning in H2 2020

• Decreasing annual cash burn in 2020

• Scaling up organization through increasing salesforce and extending relationships with world-class healthcare institutions

• Robust commercial strategy led by highly experienced team

• Strong product pipeline to capitalize on the already validated core competencies of PURE EP™ System

• Additional product pipeline covering novel therapies for autonomic nervous system disease

• Strategic partnerships with leading centers

• In March 2020, acquires the license for merimepodib, a broad-spectrum anti-viral to treat COVID-19.

Snapshot:

Key Company Data (05/19/20)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recent price:</strong></td>
<td>$10.59</td>
</tr>
<tr>
<td><strong>52-week range:</strong></td>
<td>$2.36-$12.43</td>
</tr>
<tr>
<td><strong>Primary shares i/o:</strong></td>
<td>25.94 million</td>
</tr>
<tr>
<td><strong>Public float:</strong></td>
<td>19.8 million</td>
</tr>
<tr>
<td><strong>Market cap:</strong></td>
<td>$291.6 million</td>
</tr>
<tr>
<td><strong>Average volume (1 month):</strong></td>
<td>1,000,000 shares</td>
</tr>
<tr>
<td>Board of Directors</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>Kenneth L. Londoner, MBA</td>
<td></td>
</tr>
<tr>
<td>Andrew Filler, JD</td>
<td></td>
</tr>
<tr>
<td>Donald E. Foley, MBA</td>
<td></td>
</tr>
<tr>
<td>Patrick J. Gallagher, MBA, CFA</td>
<td></td>
</tr>
<tr>
<td>Samuel E. Navarro</td>
<td></td>
</tr>
<tr>
<td>Jeffrey F. O'Donnell, Sr.</td>
<td></td>
</tr>
<tr>
<td>Martha Pease</td>
<td></td>
</tr>
<tr>
<td>David Weild IV, MBA</td>
<td></td>
</tr>
<tr>
<td>Jerry Zeldis, M.D., Ph.D</td>
<td></td>
</tr>
</tbody>
</table>